PNT Overview
Upcoming Projects (PNT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PNT)
-
Discussing the appropriate use and future of Pluvicto Radionuclide Therapy amidst the developing treatment landscape for genitourinary cancers.
Tickers: NVS, FUSN, RYZB, PNT
Executed On: Feb 02, 2024 at 08:00 AM EST -
A look at theranostic imaging and Targeted Alpha Therapy.
Tickers: LNTH, NVS, RYZB, PNT
Executed On: Jan 12, 2024 at 02:00 PM EST -
2 Week Delay: A survey on the PSMA-PET Imaging Agents with a focus on Pluvicto (Novartis Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T)
Tickers: NVS, LNTH, PNT
Executed On: Nov 10, 2022 at 05:19 PM EST -
A Third View: Discussing POINT Biopharma's SPLASH study results of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC)
Ticker: PNT
Executed On: Nov 09, 2022 at 02:00 PM EST -
A Second Look: Discussing POINT Biopharma's SPLASH study results of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC)
Ticker: PNT
Executed On: Nov 02, 2022 at 06:00 PM EDT -
Discussing POINT Biopharma's SPLASH study results of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC)
Ticker: PNT
Executed On: Oct 31, 2022 at 02:00 PM EDT -
A Second Look: Discussing Point Bio's 177Lu-PNT2002 in mCRPC after recent data presented at ESMO 2022
Tickers: PNT, NVS
Executed On: Sep 13, 2022 at 01:00 PM EDT -
Discussing the phase 3 SPLASH study (177Lu-PNT2002) from Point Biopharma, and how it may compare to Pluvicto in mCRPC
Tickers: PNT, NVS
Executed On: Aug 25, 2022 at 03:00 PM EDT
Upcoming & Overdue Catalysts (PNT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (PNT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
